Immunotherapy Considerations and Prognostic Implications

Dr. Leal addresses the complex interaction between cancer-associated LEMS as an autoimmune condition and standard SCLC therapies, particularly immunotherapy agents like checkpoint inhibitors and newer treatments like tarlatamab T-cell engagers. Many paraneoplastic syndrome patients were excluded from immunotherapy trials, yet these treatments represent standard care with improved survival outcomes. She asks how Dr. Iams approaches incorporating these therapies for patients with cancer-associated LEMS.

Dr. Iams conceptualizes cancer-associated LEMS fundamentally as an autoimmune condition, drawing parallels to accumulated experience treating patients with non-small cell lung cancer with autoimmune diseases using checkpoint inhibitors. Over time, clinicians have gained comfort with escalated monitoring approaches, with real-world cohorts demonstrating that patients with underlying autoimmune conditions often derive more benefit from checkpoint inhibitors than average patients. His anecdotal experience aligns with this observation.

Collaborative work with multiple centers, including Dr. Leal's team at Emory, demonstrates that patients with SCLC and cancer-associated LEMS can achieve excellent results with checkpoint inhibitors. However, this requires mindful approaches with rigorous patient counseling about increased risks. Patient and family perspectives become crucial: those describing pre-immunotherapy LEMS as unbearable and unwilling to risk recurrence would warrant checkpoint inhibitor avoidance. Most patients, however, prioritize cancer treatment efficacy, with potential benefits typically exceeding risks when properly monitored.

Tarlatamab presents different considerations as a bispecific T-cell engager with distinct mechanisms from general immune stimulants like PD-1 or PD-L1 inhibitors. The interaction between tarlatamab and cancer-associated LEMS remains unclear, requiring continued observation and data collection to understand safety profiles and interaction potential.

Dr. Leal references historical data suggesting patients with cancer-associated LEMS may have improved prognosis, with one study showing 17-month median survival versus 7 months for small cell lung cancer patients without LEMS, potentially reflecting antitumor immune effects. However, distinguishing between immunotherapy-driven LEMS exacerbation versus disease progression manifestations remains challenging without definitive data. Her clinical approach involves considering immunotherapy or tarlatamab for patients with well-controlled cancer-associated LEMS, stable neurologic symptoms, and absence of active immunosuppression requirements like prednisone or IVIg therapy.

Dr. Iams confirms improved prognosis observations across multiple datasets, with important stage-independent findings. Initial concerns about confounding factors, such as better immune systems controlling tumors resulting in more limited-stage disease, were addressed by analyses showing prognosis improvements regardless of stage. This stage-independent prognostic benefit provides additional impetus for comprehensive LEMS testing, as long-term SCLC survivors may have disproportionately undiagnosed LEMS cases.

Vanderbilt analysis examining tumor-infiltrating lymphocytes in small cell tumors from patients with neurologic paraneoplastic syndrome, including LEMS cases, demonstrated clear increases compared to patients without neurologic paraneoplastic syndromes. This suggests enhanced immune system engagement in paraneoplastic syndrome patients, requiring careful side effect management with amifampridine and other modalities while supporting patients through potentially longer treatment trajectories given improved prognosis expectations.